Celularity's Expansion into Asia Pacific Region
Celularity Inc. is taking significant steps in global healthcare by establishing a partnership with Genting Berhad. This collaboration focuses on introducing innovative placenta-derived allogeneic stem cell therapeutics to the Asia Pacific region, specifically in Bali, Indonesia. Celularity's advanced regenerative and cellular medicine solutions are set to revolutionize the local healthcare landscape by providing cutting-edge therapies.
A New Era for Stem Cell Therapy in Bali
The groundbreaking of Fontaine Vitale marks a major advancement in wellness and regenerative medicine. This center, located in the Sanur Special Economic Zone, will utilize Celularity's products to deliver world-class cell therapies. By focusing on wellness and aesthetics as well as regenerative medicine, Fontaine Vitale aims to cater to both local and international patients, significantly boosting medical tourism in the region.
Innovative Facilities with Global Reach
The new center is designed to align with the highest standards of medical excellence, involving local production and potentially paving the way for future manufacturing at the site under Celularity's technical guidance. This initiative promises not only to enhance the capabilities of the Bali facility but also to contribute to the broader Asia Pacific stem cell market, which is projected to grow substantially in the coming years.
Market Insights and Growth Potential
The Asia Pacific stem cell market is currently valued at an estimated USD 3.0 billion and is anticipated to grow at a compound annual growth rate (CAGR) of 16.4%, reaching approximately USD 7.2 billion by 2030. This growth is attributed to an increasing emphasis on research and development in regenerative medicine, highlighting the importance of investments in stem cell technologies and therapies.
The Vision of Celularity's Leadership
Robert J. Hariri, MD, PhD, the founder and CEO of Celularity, expressed his pride in this partnership, stating, "We are honored to collaborate with Genting Berhad to bring our innovative placenta-derived allogeneic stem cell therapy to Indonesia and the Asia Pacific region." This collaboration is set to meet the demand for high-quality stem cell and regenerative medicine treatments, offering solutions that are affordable and accessible.
About Celularity
Celularity Inc. (Nasdaq: CELU) is at the forefront of regenerative medicine, focused on developing advanced biomaterial products and innovative therapies derived from the postpartum placenta. The company targets various aging-related diseases like cancer and immune disorders, utilizing cutting-edge technologies including CAR T-cells and natural killer (NK) cells. Celularity's mission revolves around leveraging the unique biology of the placenta to address global healthcare needs effectively.
About Genting Berhad
Genting Berhad, founded in 1965, is a renowned investment holding and management company with operations in leisure and hospitality, biotechnology, and various international ventures. The group is committed to nurturing growth in multiple industries while maintaining a strong focus on innovative solutions in healthcare and beyond.
Frequently Asked Questions
What is the significance of the Fontaine Vitale center?
Fontaine Vitale aims to provide innovative stem cell therapies and wellness solutions, enhancing healthcare access in the Asia Pacific region.
How does Celularity source stem cells?
Celularity uses placenta-derived stem cells, known for their unique biological properties, sourced from its facilities in the U.S.
What is the expected growth of the Asia Pacific stem cell market?
The market is estimated to grow from USD 3.0 billion to USD 7.2 billion by 2030, reflecting a strong CAGR of 16.4%.
Who can benefit from the services offered at Fontaine Vitale?
Both local and international patients seeking advanced cell therapies for various medical and aesthetic needs can benefit from Fontaine Vitale.
What is Celularity's approach to regenerative medicine?
Celularity focuses on providing effective, accessible therapies targeting aging-related diseases and incorporates innovative research and development in its programs.
